Annie Guérin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annie Guérin has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Eric Qiong Wu
Analysis Group Inc., Boston, MA, USA
9 shared publications Eric Q. Wu
Analysis Group, Inc., Boston, MA, USA
8 shared publicationsGeneviève Gauthier
Analysis Group Boston, MAUSA
4 shared publicationsMartin Cloutier
Analysis Group Boston, MAUSA
4 shared publications- Andrew Peng Yu
Analysis Group, Inc., Boston, MA, USA
3 shared publications Eric Wu
Analysis Group Boston, MAUSA
3 shared publications
Latest Publications
- 1 November 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (11) , S314-S315
PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States
- 1 November 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (11) , S314-S315
PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20549
Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.
E20549 Background: A Phase 2 clinical trial of veliparib + carboplatin (C) and paclitaxel (P) in patients (pts) with previously untreated metastatic/advanced NSCLC showed that veliparib may improve survival compared to placebo and that smoking history was a strong predictor of efficacy for veliparib+CP. This study compares quality of life (QoL) by smoking status in pts receiving veliparib+CP vs placebo+CP. Methods: This study is a secondary analysis of a Phase 2 clinical trial (NCT01560104) where pts were randomized 2:1 to veliparib+CP (120mg BID) or placebo+CP for up to 6 treatment cycles (study period). Pts with ≥ 1 QoL measurement at baseline (pre-treatment initiation) and during ≥ 1 cycle were selected and stratified by smoking status in the year preceding the trial (smokers [S] vs non-smokers [NS]). Proportions of pts with a QoL improvement (QoL+)/deterioration (QoL-) from baseline achieving minimal important difference ( ≥ 10 points on a 100-point scale) across the study period were compared by treatment and smoking status using generalized estimating equation models adjusted for baseline QoL score, gender, and ECOG, for each of the 22 EORTC QLQ-C15-PAL/LC13 questionnaire items. Results: Among 143 pts (657 pt-cycles), mean age was 62 years, 67% were male, and 59% were S. In S, veliparib+CP pts had better or non-different QoL compared to placebo+CP pts; a higher proportion of veliparib+CP pts had QoL+ for dyspnea (odds ratio [OR] = 3.63) and a lower proportion of pts had QoL- for physical functioning (OR = 0.46), appetite loss (OR = 0.37), and dysphagia (OR = 0.12), all p < .05. In veliparib+CP pts, S had better or non-different QoL compared to NS (emotional functioning: both QoL+ and QoL- OR = 2.80 and 0.38, respectively; pain in chest: QoL+ OR = 3.86; coughing: QoL- OR = 0.48; all p < .05). The magnitude of the difference in QoL for S vs NS was larger or non-different in veliparib+CP pts compared to placebo+CP pts (dyspnea: QoL+ OR = 8.48; appetite loss: QoL+ OR = 11.54, QoL- OR = 0.27; dysphagia: QoL- OR = 0.05; all p < .05). Conclusions: Smokers receiving veliparib+CP had better or non-different QoL compared to both non-smokers receiving veliparib+CP and to smokers receiving placebo+CP. Clinical trial information: NCT01560104.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20549
Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.
E20549 Background: A Phase 2 clinical trial of veliparib + carboplatin (C) and paclitaxel (P) in patients (pts) with previously untreated metastatic/advanced NSCLC showed that veliparib may improve survival compared to placebo and that smoking history was a strong predictor of efficacy for veliparib+CP. This study compares quality of life (QoL) by smoking status in pts receiving veliparib+CP vs placebo+CP. Methods: This study is a secondary analysis of a Phase 2 clinical trial (NCT01560104) where pts were randomized 2:1 to veliparib+CP (120mg BID) or placebo+CP for up to 6 treatment cycles (study period). Pts with ≥ 1 QoL measurement at baseline (pre-treatment initiation) and during ≥ 1 cycle were selected and stratified by smoking status in the year preceding the trial (smokers [S] vs non-smokers [NS]). Proportions of pts with a QoL improvement (QoL+)/deterioration (QoL-) from baseline achieving minimal important difference ( ≥ 10 points on a 100-point scale) across the study period were compared by treatment and smoking status using generalized estimating equation models adjusted for baseline QoL score, gender, and ECOG, for each of the 22 EORTC QLQ-C15-PAL/LC13 questionnaire items. Results: Among 143 pts (657 pt-cycles), mean age was 62 years, 67% were male, and 59% were S. In S, veliparib+CP pts had better or non-different QoL compared to placebo+CP pts; a higher proportion of veliparib+CP pts had QoL+ for dyspnea (odds ratio [OR] = 3.63) and a lower proportion of pts had QoL- for physical functioning (OR = 0.46), appetite loss (OR = 0.37), and dysphagia (OR = 0.12), all p < .05. In veliparib+CP pts, S had better or non-different QoL compared to NS (emotional functioning: both QoL+ and QoL- OR = 2.80 and 0.38, respectively; pain in chest: QoL+ OR = 3.86; coughing: QoL- OR = 0.48; all p < .05). The magnitude of the difference in QoL for S vs NS was larger or non-different in veliparib+CP pts compared to placebo+CP pts (dyspnea: QoL+ OR = 8.48; appetite loss: QoL+ OR = 11.54, QoL- OR = 0.27; dysphagia: QoL- OR = 0.05; all p < .05). Conclusions: Smokers receiving veliparib+CP had better or non-different QoL compared to both non-smokers receiving veliparib+CP and to smokers receiving placebo+CP. Clinical trial information: NCT01560104.
- 21 December 2015
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 19 (4) , 414-423
Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2? metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis
To analyze medical costs and healthcare resource utilization (HRU) associated with everolimus-based therapy or chemotherapy among post-menopausal women with hormone-receptor-positive, human-epidermal-growth-factor-receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC).
- 21 December 2015
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 19 (4) , 414-423
Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2? metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis
To analyze medical costs and healthcare resource utilization (HRU) associated with everolimus-based therapy or chemotherapy among post-menopausal women with hormone-receptor-positive, human-epidermal-growth-factor-receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC).
- 20 July 2015
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 31 (8) , 1611-1620
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study
To describe real-world treatment patterns of patients receiving colchicine or other treatments during a gout-related emergency room or acute care facility (ER/ACF) visit.
- 20 July 2015
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 31 (8) , 1611-1620
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study
To describe real-world treatment patterns of patients receiving colchicine or other treatments during a gout-related emergency room or acute care facility (ER/ACF) visit.
- 1 June 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (3) , 307-312
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
- 1 June 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (3) , 307-312
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
- Open Access
- 1 August 2014
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (9) , 901-908
Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting
Background.: Existing treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs). This study aimed to identify AEs associated with chemotherapies commonly used in mBC treatment (phase 1) and to quantify the economic impact of these AEs (phase 2). Materials and Methods.: Patients in phase 1 had at least one claim for therapy for mBC, with at least one episode with single or multiple agents. The most common chemotherapy-related complications were identified using medical and pharmacy claims data. In phase 2, patients meeting study criteria were divided into four treatment cohorts by the line of treatment and chemotherapy received: first-line taxane-treated patients, second-line taxane-treated patients, first-line capecitabine-treated patients, and second-line capecitabine-treated patients. Average monthly AE-related health care costs per cohort were stratified by cost component. Total monthly costs per number of AEs were also calculated. Results.: On average, patients in phase 1 (n = 1,551) had 2 episodes of treatment, with a mean duration of 131 days. The most frequently noted complications were anemia (50.7% of mBC treatment episodes), bilirubin elevation (26.4%), and leukopenia (24.8%). In phase 2, costs related to AEs were primarily driven by incremental inpatient, outpatient, and pharmacy costs. Increases in average monthly costs ranged from $854 (9.0%) to $5,320 (69.5%), according to cohort. Overall costs increased with increasing numbers of AEs. Conclusion.: Chemotherapy-related AEs in patients with mBC are associated with a substantial economic burden that increases with the number of AEs reported.
- 1 August 2014
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (9) , 901-908
Open AccessInvestigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting
Background.: Existing treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs). This study aimed to identify AEs associated with chemotherapies commonly used in mBC treatment (phase 1) and to quantify the economic impact of these AEs (phase 2). Materials and Methods.: Patients in phase 1 had at least one claim for therapy for mBC, with at least one episode with single or multiple agents. The most common chemotherapy-related complications were identified using medical and pharmacy claims data. In phase 2, patients meeting study criteria were divided into four treatment cohorts by the line of treatment and chemotherapy received: first-line taxane-treated patients, second-line taxane-treated patients, first-line capecitabine-treated patients, and second-line capecitabine-treated patients. Average monthly AE-related health care costs per cohort were stratified by cost component. Total monthly costs per number of AEs were also calculated. Results.: On average, patients in phase 1 (n = 1,551) had 2 episodes of treatment, with a mean duration of 131 days. The most frequently noted complications were anemia (50.7% of mBC treatment episodes), bilirubin elevation (26.4%), and leukopenia (24.8%). In phase 2, costs related to AEs were primarily driven by incremental inpatient, outpatient, and pharmacy costs. Increases in average monthly costs ranged from $854 (9.0%) to $5,320 (69.5%), according to cohort. Overall costs increased with increasing numbers of AEs. Conclusion.: Chemotherapy-related AEs in patients with mBC are associated with a substantial economic burden that increases with the number of AEs reported.
- Open Access
- 8 May 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 1-11
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in patients with metastatic breast cancer (mBC) receiving HER2 directed therapy. This study evaluated these outcomes in patients receiving trastuzumab or lapatinib. Adult women with mBC, who were initiated on trastuzumab or lapatinib, on or after March 13, 2007, were selected from the US-based PharMetrics® Integrated Database (2000–2011). Patients were required to be continuously enrolled in their healthcare plan for ≥6 months prior to and ≥30 days following trastuzumab or lapatinib initiation. Trastuzumab or lapatinib discontinuation rates (defined as a gap ≥45 consecutive days) were compared using multivariate Cox proportional-hazards models. HRU and monthly healthcare cost differences were estimated using multivariate negative binomial regression models and generalized linear models, respectively. Among the 643 patients who met the inclusion criteria, 381 and 262 patients were included in the trastuzumab and lapatinib groups, respectively. The majority of the 262 patients receiving lapatinib previously received trastuzumab (N = 171 [65.3%]). After adjustment for potential confounders, when compared to trastuzumab patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of medical visits associated with treatment administration (IRR = 0.34; P < 0.001). There were no significant differences between the two groups in total monthly healthcare costs ($11,920 vs. $11,898 for trastuzumab and lapatinib patients, respectively; P = 0.451). Findings from our study show that, irrespective of the treatment initiated at index date, disease management in patients with mBC is associated with similar and substantial healthcare costs. Any differences in specific components of healthcare costs were associated with differences in the mode of treatment administration. Approximately 50% of all costs were non-drug related, and future studies should focus on how these costs may be controlled, regardless of mode of treatment administration.
- 8 May 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 1-11
Open AccessComparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in patients with metastatic breast cancer (mBC) receiving HER2 directed therapy. This study evaluated these outcomes in patients receiving trastuzumab or lapatinib. Adult women with mBC, who were initiated on trastuzumab or lapatinib, on or after March 13, 2007, were selected from the US-based PharMetrics® Integrated Database (2000–2011). Patients were required to be continuously enrolled in their healthcare plan for ≥6 months prior to and ≥30 days following trastuzumab or lapatinib initiation. Trastuzumab or lapatinib discontinuation rates (defined as a gap ≥45 consecutive days) were compared using multivariate Cox proportional-hazards models. HRU and monthly healthcare cost differences were estimated using multivariate negative binomial regression models and generalized linear models, respectively. Among the 643 patients who met the inclusion criteria, 381 and 262 patients were included in the trastuzumab and lapatinib groups, respectively. The majority of the 262 patients receiving lapatinib previously received trastuzumab (N = 171 [65.3%]). After adjustment for potential confounders, when compared to trastuzumab patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of medical visits associated with treatment administration (IRR = 0.34; P < 0.001). There were no significant differences between the two groups in total monthly healthcare costs ($11,920 vs. $11,898 for trastuzumab and lapatinib patients, respectively; P = 0.451). Findings from our study show that, irrespective of the treatment initiated at index date, disease management in patients with mBC is associated with similar and substantial healthcare costs. Any differences in specific components of healthcare costs were associated with differences in the mode of treatment administration. Approximately 50% of all costs were non-drug related, and future studies should focus on how these costs may be controlled, regardless of mode of treatment administration.
- 10 September 2013
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (11) , 1275-1289
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
Objective: To compare treatment persistence in attention-deficit/hyperactivity disorder (ADHD) of patients initiated on lisdexamfetamine (LDX) vs other ADHD medications. Methods: A large US administrative claims database was used to select ADHD patients who initiated an ADHD medication (index treatment) during/after 2007. Patients were classified, based on age and previous treatment status, as treatment-naïve or previously treated children and adolescents (6–17 years) and treatment-naïve or previously treated adults (18 years and older). Furthermore, patients were classified into seven mutually exclusive treatment groups, based on their index treatment: LDX, atomoxetine (ATX), osmotic-release methylphenidate hydrochloride long-acting (OROS MPH), other methylphenidate/dexmethylphenidate short-acting (MPH SA) and long-acting (MPH LA), and amphetamine/dextroamphetamine short acting (AMPH SA) and long-acting (AMPH LA). Treatment persistence, analyzed through discontinuation (interruption of the index treatment for ≥30 consecutive days), was compared between treatment groups using multivariate Cox proportional hazards. Patients were followed until first treatment discontinuation or up to 12 months after the initiation of the index treatment, whichever occurred first. Results: Among children and adolescents, LDX patients had a significantly lower discontinuation rate compared to other treatment groups (range hazard ratios [HRs]; 1.04–2.26; all p < 0.05), except when compared to treatment-naïve patients on ATX and OROS MPH, where no statistically significant differences were found and where LDX had a higher risk of discontinuation, respectively. Among adults, LDX patients had a significantly lower discontinuation rate compared to patients in other treatment groups (range HR; 1.14–1.86; all p < 0.05), except for the comparison with AMPH LA patients, where differences were not statistically significant. Limitations: This study did not control for ADHD severity. Conclusion: LDX-treated patients were associated with higher persistence compared to patients initiated on other ADHD medications, except for the comparisons with OROS MPH and ATX treated patients in treatment-naïve children and adolescents and AMPH LA-treated patients in adults.
- 10 September 2013
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (11) , 1275-1289
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
Objective: To compare treatment persistence in attention-deficit/hyperactivity disorder (ADHD) of patients initiated on lisdexamfetamine (LDX) vs other ADHD medications. Methods: A large US administrative claims database was used to select ADHD patients who initiated an ADHD medication (index treatment) during/after 2007. Patients were classified, based on age and previous treatment status, as treatment-naïve or previously treated children and adolescents (6–17 years) and treatment-naïve or previously treated adults (18 years and older). Furthermore, patients were classified into seven mutually exclusive treatment groups, based on their index treatment: LDX, atomoxetine (ATX), osmotic-release methylphenidate hydrochloride long-acting (OROS MPH), other methylphenidate/dexmethylphenidate short-acting (MPH SA) and long-acting (MPH LA), and amphetamine/dextroamphetamine short acting (AMPH SA) and long-acting (AMPH LA). Treatment persistence, analyzed through discontinuation (interruption of the index treatment for ≥30 consecutive days), was compared between treatment groups using multivariate Cox proportional hazards. Patients were followed until first treatment discontinuation or up to 12 months after the initiation of the index treatment, whichever occurred first. Results: Among children and adolescents, LDX patients had a significantly lower discontinuation rate compared to other treatment groups (range hazard ratios [HRs]; 1.04–2.26; all p < 0.05), except when compared to treatment-naïve patients on ATX and OROS MPH, where no statistically significant differences were found and where LDX had a higher risk of discontinuation, respectively. Among adults, LDX patients had a significantly lower discontinuation rate compared to patients in other treatment groups (range HR; 1.14–1.86; all p < 0.05), except for the comparison with AMPH LA patients, where differences were not statistically significant. Limitations: This study did not control for ADHD severity. Conclusion: LDX-treated patients were associated with higher persistence compared to patients initiated on other ADHD medications, except for the comparisons with OROS MPH and ATX treated patients in treatment-naïve children and adolescents and AMPH LA-treated patients in adults.
- 19 August 2013
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 16 (10) , 1203-1215
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults
Objective: To compare therapy augmentation and deviation rates from the recommended once-daily dosing regimen in Attention Deficit Hyperactivity Disorder (ADHD) patients initiated on lisdexamfetamine (LDX) vs other once-daily Food and Drug Administration (FDA) approved stimulants. Methods: ADHD patients initiated on a long-acting ADHD stimulant medication (index medication) in/after 2007 were selected from a large US administrative claims database. Patients were required to be persistent for ≥90 days and continuously enrolled in their healthcare plan for ≥12 months following treatment initiation date. Based on age and previous treatment status, patients were classified into treatment-naïve children and adolescents (6–17 years old), previously treated children and adolescents, treatment-naïve adults (≥18 years old), and previously treated adults. Furthermore, patients were classified into four mutually exclusive treatment groups, based on index medication: lisdexamfetamine (LDX), osmotic release methylphenidate hydrochloride long-acting (OROS MPH), other methylphenidate/dexmethylphenidate long-acting (MPH LA), and amphetamine/dextroamphetamine long-acting (AMPH LA). The average daily consumption was measured as the quantity of index medication supplied in the 12-month study period divided by the total number of days of supply. Therapy augmentation was defined as the use of another ADHD medication concomitantly with the index medication for ≥28 consecutive days. Therapy augmentation and deviation rates from the recommended once-daily dosing regimen were compared between treatment groups using multivariate logistic regression models. Results: Compared to the other treatment groups, LDX patients were less likely to augment with another ADHD medication (range odds ratios [OR]; 1.28–3.30) and to deviate from the recommended once-daily dosing regimen (range OR; 1.73–4.55), except for previously treated adult patients, where therapy augmentation differences were not statistically significant when compared to OROS MPH and MPH LA patients. Limitations: This study did not control for ADHD severity. Conclusion: Overall, compared to LDX-treated patients, patients initiated on other ADHD medications were equally or more likely to have a therapy augmentation and more likely to deviate from the recommended once-daily dosing regimen.
- 19 August 2013
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 16 (10) , 1203-1215
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults
Objective: To compare therapy augmentation and deviation rates from the recommended once-daily dosing regimen in Attention Deficit Hyperactivity Disorder (ADHD) patients initiated on lisdexamfetamine (LDX) vs other once-daily Food and Drug Administration (FDA) approved stimulants. Methods: ADHD patients initiated on a long-acting ADHD stimulant medication (index medication) in/after 2007 were selected from a large US administrative claims database. Patients were required to be persistent for ≥90 days and continuously enrolled in their healthcare plan for ≥12 months following treatment initiation date. Based on age and previous treatment status, patients were classified into treatment-naïve children and adolescents (6–17 years old), previously treated children and adolescents, treatment-naïve adults (≥18 years old), and previously treated adults. Furthermore, patients were classified into four mutually exclusive treatment groups, based on index medication: lisdexamfetamine (LDX), osmotic release methylphenidate hydrochloride long-acting (OROS MPH), other methylphenidate/dexmethylphenidate long-acting (MPH LA), and amphetamine/dextroamphetamine long-acting (AMPH LA). The average daily consumption was measured as the quantity of index medication supplied in the 12-month study period divided by the total number of days of supply. Therapy augmentation was defined as the use of another ADHD medication concomitantly with the index medication for ≥28 consecutive days. Therapy augmentation and deviation rates from the recommended once-daily dosing regimen were compared between treatment groups using multivariate logistic regression models. Results: Compared to the other treatment groups, LDX patients were less likely to augment with another ADHD medication (range odds ratios [OR]; 1.28–3.30) and to deviate from the recommended once-daily dosing regimen (range OR; 1.73–4.55), except for previously treated adult patients, where therapy augmentation differences were not statistically significant when compared to OROS MPH and MPH LA patients. Limitations: This study did not control for ADHD severity. Conclusion: Overall, compared to LDX-treated patients, patients initiated on other ADHD medications were equally or more likely to have a therapy augmentation and more likely to deviate from the recommended once-daily dosing regimen.